The competition regulator has detailed “significant” concerns with Cochlearâs proposed acquisition of Oticon Medical, saying Thursday a tie-up would cut to three the number of cochlear implant suppliers in Australia.
Accounting firm Pitcher Partners has hit back at a lawsuit by the former owner of fitness franchise Zap Fitness claiming the firm failed to properly advise on a troubled share buy-back scheme that spawned litigation the company paid $4.25 million to settle.
Former CEO of failed van Eyk Research has been sentenced to 15 months’ imprisonment after admitting he breached his duties as director of a subsidiary to dishonestly retain control of the company.
Nuix has pointed the finger at its accountant PricewaterhouseCoopers in the software company’s defence to a class action over a prospectus for its $1.8 billion IPO two years ago.
Fund manager Salter Brothers has been awarded more than $8 million in a breach of warranty suit against former Hendry Group boss Emma Hendry and related parties after they failed to comply with court orders in the case.
A judge has tossed a brokerâs lawsuit against NAB and its former subsidiary FAST, finding the bank was entitled to terminate its accreditation over the use of a banned brokerâs trail book.
A mobile network sharing agreement between Telstra and TPG is likely to boost the companies’ services to customers but could lead to TPG raising prices, the competition regulator said Friday.
Two former executives of defunct electronics retailer Dick Smith have asked the High Court to hear their challenge to a $11.8 million damages award for approving a dividend payment the company could not afford.
The former CEO of Blue Star Helium has asked the High Court to throw out a $40,000 penalty and four-year ban imposed on him after the company failed to disclose to shareholders the identity of the buyer behind a botched sale of Texas oil assets.
The Australian unit of Mylan is challenging the ATO’s rejection of a $48 million deduction for 2020 in the generic drug company’s latest spat with the tax office over interest on loans to fund its $1.2 billion acquisition of generic drug maker Alphapharm.